Abstract
Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1482-1491 |
| Number of pages | 10 |
| Journal | Archives of Pathology and Laboratory Medicine |
| Volume | 136 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2012 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Medical Laboratory Technology
Cite this
Lung cancer genotype-based therapy and predictive biomarkers present and future. / Cagle, Philip T.; Allen, Timothy Craig.
In: Archives of Pathology and Laboratory Medicine, Vol. 136, No. 12, 12.2012, p. 1482-1491.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lung cancer genotype-based therapy and predictive biomarkers present and future
AU - Cagle, Philip T.
AU - Allen, Timothy Craig
PY - 2012/12
Y1 - 2012/12
N2 - Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.
AB - Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=84870858928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870858928&partnerID=8YFLogxK
U2 - 10.5858/arpa.2012-0508-RA
DO - 10.5858/arpa.2012-0508-RA
M3 - Article
C2 - 23194040
AN - SCOPUS:84870858928
VL - 136
SP - 1482
EP - 1491
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
SN - 0003-9985
IS - 12
ER -